Study type: Human research · Status: Verified against declared source

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.

Journal of medicine and life · 2017

Study scale: Three neurological hospitals in the Islamic Republic of Iran participated in this study.

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Background and Purpose:

Methods

Methods.

Scale or participants

Three neurological hospitals in the Islamic Republic of Iran participated in this study.

Key findings

Results.The estimated effect size on the change from baseline in the NIH Stroke Scale on day 30 indicated a medium to large superiority of cerebrolysin compared to placebo (Mann-Whitney [MW] 0.66; 95% confidence interval [CI] 0.55-0.78, P=0.005).

Limitations and uncertainty

Conclusions.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.